



The first connected diabetes management platform

Press release

Cellnovo announces its Q4 and Full Year 2018 Sales

*Strong growth in Q4 sales
Annual revenues more than doubled compared to 2017*

Paris, France, January 15, 2019 – Cellnovo Group (“Cellnovo” or the “Company” - CLNV: EN Paris), a medical technology company marketing the first connected diabetes management platform comprised of a discreet, wearable micro-pump that communicates via Bluetooth® with a locked-down Android™ smartphone, today reports its revenue from sales for the fourth quarter of 2018, and the full year 2018.

	Annual		Quarterly – 3 months	
	2018	2017	Q4 2018	Q4 2017
Sales	€2,569k	€1,058k	€1,050k	€369k
New systems sold (units)	674	203	347	58

During the fourth quarter of the year, the Company's sales amounted to €1,050k, compared with €369k for the same period in the previous year. Fourth quarter revenue alone was equivalent to the total annual sales for the previous year and represents a +58% increase from the previous quarter (Q3: €665k.) For the full year 2018, Cellnovo reported sales of €2,569k, up +142% compared with the previous year. This strong revenue growth is the result of the start of large-scale production of insulin cartridges last June and the roll-out of the new Gen 3 System in September 2018.

Cellnovo sold 347 new systems in the fourth quarter of 2018, compared to 58 in the fourth quarter of 2017, bringing the total number of systems sold in 2018 to 674 and the total number of systems sold since launch to 1,506.

Sophie Baratte, Chief Executive Officer of Cellnovo, commented: “*The strong sales growth in the last quarter of 2018 confirms the positive response of the type 1 diabetes community to the new version of our unique connected system that combines a micro-pump for insulin delivery with a locked-down Android™ smartphone. 2018 marked the successful industrialization and ramp-up of insulin cartridge production with Flex. The improved performance and user experience of our new Gen 3 System, which provide real added value for patients and caregivers, allow us to anticipate strong growth in 2019 in a market that remains as fast-growing and dynamic as ever.*”

•••

About Cellnovo (Euronext: CLNV)

Cellnovo Group is global innovative medical technology company supporting the needs and desires of people with type 1 diabetes. Cellnovo has developed and markets a novel diabetes management system, which is a connected platform that aims to make life easier for people with type 1 diabetes. Cellnovo's insulin delivery system comprises a discreet, wearable micro-pump that communicates via Bluetooth® with a locked-down Android™ smartphone. This unique system allows optimal management of insulin dosing and delivery while ensuring freedom of movement and peace of mind. Thanks to the transmission of data in real time, the patient's status can be seamlessly monitored



The first connected diabetes management platform

by family members and healthcare professionals. Cellnovo is currently participating in several major Artificial Pancreas projects with TypeZero, PEPPER and Diabeloop, to develop fully automated, closed-loop insulin delivery systems.

For more information go to www.cellnovo.com

Cellnovo is listed on Euronext,
Compartment C
ISIN: FR0012633360 – Ticker:
CLNV)



Cellnovo

Chief Executive Officer
Sophie Baratte
investors@cellnovo.com

NewCap

Investor Relations
Tristan Roquet Montégon
+ 33 1 44 71 00 16
cellnovo@newcap.eu

NewCap

Media Relations in France
Nicolas Merigeau
+ 33 1 44 71 94 98
cellnovo@newcap.eu